Nuformix (LON:NFX) Announces Quarterly Earnings Results

Nuformix (LON:NFX) released its quarterly earnings data on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share for the quarter, Digital Look Earnings reports.

Nuformix Trading Down 14.1 %

Shares of NFX opened at GBX 0.07 ($0.00) on Thursday. The stock’s fifty day simple moving average is GBX 0.06 and its 200-day simple moving average is GBX 0.10. The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17. The firm has a market capitalization of £598,096.30, a PE ratio of -1.63 and a beta of 1.22. Nuformix has a 12-month low of GBX 0.04 ($0.00) and a 12-month high of GBX 0.34 ($0.00).

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.